Once-Daily Gastroretentive Gabapentin for Treatment of Postherpetic Neuralgia

• Dworkin RH , PortenoyRK. Pain and its persistence in herpes zoster. Pain67(2–3) , 241–251 (1996).
   PubMed Web of Science ®Google Scholar
• Johnson RW , WasnerG, SaddierP et al. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev. Neurother. 7(11) , 1581–1595 (2007).
   PubMedGoogle Scholar
• Cunningham AL , DworkinRH. The management of post-herpetic neuralgia. BMJ321(7264) , 778–779 (2000).
   PubMedGoogle Scholar
• Oxman MN , LevinMJ, JohnsonGR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352(22) , 2271–2284 (2005).
   PubMed Web of Science ®Google Scholar
• Mao J , ChenLL. Gabapentin in pain management. Anesth. Analg.91(3) , 680–687 (2000).
   PubMed Web of Science ®Google Scholar
• Rice ASC , MatonS, GroupPNS. Gabapentin in posterpetic neuralgia: a randomised, double blind, placebo controlled study. Pain94(2) , 215–224 (2001).
   PubMed Web of Science ®Google Scholar
• Rowbotham M , HardenN, StaceyB et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280(21) , 1837–1842 (1998).
   PubMed Web of Science ®Google Scholar
• Kriel RL , BirnbaumAK, CloydJC et al. Failure of absorption of gabapentin after rectal administration. Epilepsia 38(11) , 1242–1244 (1997).
   PubMed Web of Science ®Google Scholar
• Stewart BH , KuglerAR, ThompsonPR et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm. Res. 10(2) , 276–281 (1993).
   PubMed Web of Science ®Google Scholar
• Mclean MJ . Gabapentin. Epilepsia36(Suppl. 2) , S73–S86 (1995).
   PubMedGoogle Scholar
• Claxton AJ , CramerJ, PierceC. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther.23(8) , 1296–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Eisen SA , MillerDK, WoodwardRS et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch. Intern. Med. 150(9) , 1881–1884 (1990).
   PubMed Web of Science ®Google Scholar
• Vollmer KO , Von Hodenberg A, Kolle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung36(5) , 830–839 (1986).
   PubMed Web of Science ®Google Scholar
• Chen C , CowlesVE, HouE. Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and effect of dose escalation and food. J. Clin. Pharmacol.51(3) , 346–358 (2011).
   PubMed Web of Science ®Google Scholar
• Hou SY , CowlesVE, BernerB. Gastric retentive dosage forms: a review. Crit. Rev. Ther. Drug Carrier Syst.20(6) , 459–497 (2003).
   PubMed Web of Science ®Google Scholar
• Waterman KC . A critical review of gastric retentive controlled drug delivery. Pharm. Dev. Technol.12(1) , 1–10 (2007).
   PubMed Web of Science ®Google Scholar
• Chien YW . Oral drug delivery and delivery systems. In: Novel Drug Delivery Systems. Marcel Dekker, NY, USA, 159–163 (1992).
   Google Scholar
• Gordi T , HouE, KasichayanulaS et al. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin. Ther. 30(5) , 909–916 (2008).
   PubMed Web of Science ®Google Scholar
• Irving G , JensenM, CramerM et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin. J. Pain 25(3) , 185–192 (2009).
   PubMed Web of Science ®Google Scholar
• Sang CN , SathyanarayanaR, SweeneyM et al. Once-daily gabapentin for the treatment of postherpetic neuralgia (PHN): results of a multicenter, randomized, double-blind, placebo-controlled Phase 3 study. Clin. J. Pain (2012) (In Press).
   Google Scholar
• Wallace MS , IrvingG, CowlesVE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clin. Drug Investig.30(11) , 765–776 (2010).
   PubMed Web of Science ®Google Scholar
• Koltun A , TarkM, SweeneyM. Once-daily gabapentin for the treatment of postherpetic neuralgia (PHN). Presented at: Midwest Pain Society 35th Scientific Meeting. Chicago, IL, USA, 28–29 October 2011.
   Google Scholar
• Striano P , StrianoS. Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. Drugs Today (Barc.)44(5) , 353–368 (2008).
   PubMed Web of Science ®Google Scholar
• Elwes RD , BinnieCD. Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin. Pharmacokinet.30(6) , 403–415 (1996).
   PubMed Web of Science ®Google Scholar
• Eckhardt K , AmmonS, HofmannU et al. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth. Analg. 91(1) , 185–191 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson P , HalpernR, BeckerL et al. Titration with gabapentin and pregabalin in patients with postherpetic neuralgia (PHN). Presented at: American Academy of Pain Medicine‘s Annual Meeting. Palm Springs, CA, USA, 23–26 February 2012.
   Google Scholar

▪ Websites

• Neurontin® (gabapentin) Capules, Neurontin® (gabapentin) Tablets, Neurontin® (gabapentin) Oral Solution. US prescribing information. April 2009. www.pfizer.com/files/products/uspi_neurontin.pdf (Accessed 29January2010)
   Google Scholar
• GRALISE (gabapentin) tablets. US prescribing information. January 2011. www.gralise.com/lib/PDFS/GRALISE_PI.pdf (Accessed 3February2011)
   Google Scholar